BRAF and metastatic melanoma: Although development of targeted therapy in melanomas carrying BRAF mutations has revolutionized treatment, a significant number of patients with BRAF V600E metastatic melanoma experience recurrence within a few months upon treatment with the BRAF inhibitor vemurafenib 1 or the MEK inhibitor trametinib 2.